⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14401657 | 0.74 | CYP17A1 (0.33) | — | |
| SCHEMBL27759827 | 0.68 | RIPK1 (0.47) | — | |
| SCHEMBL22287254 | 0.66 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL13411813 | 0.63 | ADH5 (0.36) | — | |
| SCHEMBL2915311 | 0.62 | SLC6A4 (0.40) | — | |
| SCHEMBL6117683 | 0.61 | CYP1A2 (0.33) | — | |
| SCHEMBL3699462 | 0.59 | ESR2 (0.38) | — | |
| SCHEMBL17254440 | 0.58 | ESR1 (0.33) | — | |
| SCHEMBL703646 | 0.58 | LMNA (0.43) | — | |
| SCHEMBL25951392 | 0.58 | CYP17A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2025-01-28 | — | — | US | disclosed |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | NOVARTIS AG (CH) | 2023-03-23 | — | — | US | disclosed |
| US-20220024981-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2022-01-27 | — | — | US | disclosed |
| EP-3887365-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| EP-3887363-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| EP-3887388-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| US-20210252103-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2021-08-19 | — | — | US | disclosed |
| US-11026993-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2021-06-08 | — | — | US | disclosed |
| EP-3778557-A1 | COMBINATIONS COMPRISING A SUBSTITUTED BIPHENYLBUTANOIC ESTER DERIVATIVE AS NEP INHIBITOR AND VALSARTAN | Novartis AG (CH) | 2021-02-17 | — | — | EP | disclosed |
| WO-2010136474-A2 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-7799780-B2 | Condensed imidazole derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799780-B2 | Condensed imidazole derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799780-B2 | Condensed imidazole derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| EP-2004657-B1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-09-01 | — | — | EP | disclosed |
| US-20090012068-A1 | Condensed Imidazole Derivatives as Aldosterone Synthase Inhibitors | NOVARTIS AG (CH) | 2009-01-08 | — | — | US | disclosed |
| US-20090012068-A1 | Condensed Imidazole Derivatives as Aldosterone Synthase Inhibitors | NOVARTIS AG (CH) | 2009-01-08 | — | — | US | disclosed |
| US-20090012068-A1 | Condensed Imidazole Derivatives as Aldosterone Synthase Inhibitors | NOVARTIS AG (CH) | 2009-01-08 | — | — | US | disclosed |
| WO-2007116097-A1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2007-10-18 | — | — | WO | disclosed |